Evidence map›Paper›PMID 38897294›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2024

Cavitation monitoring, treatment strategy, and acoustic simulations of focused ultrasound blood-brain barrier disruption in patients with glioblastoma.

Nathan McDannold, Patrick Y Wen, David A Reardon, Stecia-Marie Fletcher, Alexandra J Golby

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nathan McDannoldDepartment of Radiology, Brigham and Women's Hospital, Boston, MA, United States of America. Electronic address: njm@bwh.harvard.edu.
Patrick Y WenDepartment of Neuro-oncology, Dana Farber Cancer Institute, Boston, MA, United States of America.
David A ReardonDepartment of Neuro-oncology, Dana Farber Cancer Institute, Boston, MA, United States of America.
Stecia-Marie FletcherDepartment of Radiology, Brigham and Women's Hospital, Boston, MA, United States of America.
Alexandra J GolbyDepartment of Radiology, Brigham and Women's Hospital, Boston, MA, United States of America; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, United States of America.

Funding

Optimization of ultrasound-mediated drug delivery to the brain under clinically relevant conditionsR01EB033307 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI MCDANNOLD, NATHAN J. · 2022 to 2025
$2.0M
NIBIB NIH HHS R01 EB033307
6 · The paper itself

Abstract

purposeWe report our experience disrupting the blood-brain barrier (BBB) to improve drug delivery in glioblastoma patients receiving temozolomide chemotherapy. The goals of this retrospective analysis were to compare MRI-based measures of BBB disruption and vascular damage to the exposure levels, acoustic emissions data, and acoustic simulations. We also simulated the cavitation detectors.

methodsMonthly BBB disruption (BBBD) was performed using a 220 kHz hemispherical phased array focused ultrasound system (Exablate Neuro, InSightec) and Definity microbubbles (Lantheus) over 38 sessions in nine patients. Exposure levels were actively controlled via the cavitation dose obtained by monitoring subharmonic acoustic emissions. The acoustic field and sensitivity profile of the cavitation detection system were simulated. Exposure levels and cavitation metrics were compared to the level of BBBD evident in contrast-enhanced MRI and to hypointense regions in T2*-weighted MRI.

resultsOur treatment strategy evolved from using a relatively high cavitation dose goal to a lower goal and longer sonication duration and ultimately resulted in BBBD across the treatment volume with minimal petechiae. Subsonication-level feedback control of the exposure using acoustic emissions also improved consistency. Simulations of the acoustic field suggest that reflections and standing waves appear when the focus is placed near the skull, but their effects can be mitigated with aberration correction. Simulating the cavitation detectors suggest variations in the sensitivity profile across the treatment volume and between patients. A correlation was observed with the cavitation dose, BBBD and petechial hemorrhage in 8/9 patients, but substantial variability was evident. Analysis of the cavitation spectra found that most bursts did not contain wideband emissions, a signature of inertial cavitation, but biggest contribution to the cavitation dose - the metric used to control the procedure - came from bursts with wideband emissions.

conclusionUsing a low subharmonic cavitation dose with a longer duration resulted in BBBD with minimal petechiae. The correlation between cavitation dose and outcomes demonstrates the benefits of feedback control based on acoustic emissions, although more work is needed to reduce variability. Acoustic simulations could improve focusing near the skull and inform our analysis of acoustic emissions. Monitoring additional frequency bands and improving the sensitivity of the cavitation detection could provide signatures of microbubble activity associated with BBB disruption that were undetected here and could improve our ability to achieve BBB disruption without vascular damage.

Indexed as

Blood-Brain BarrierBrain NeoplasmsGlioblastomaMagnetic Resonance ImagingMicrobubblesAcousticsAdultAgedAntineoplastic Agents, AlkylatingComputer SimulationDrug Delivery SystemsFemaleHumansMaleMiddle AgedRetrospective StudiesAntineoplastic Agents, AlkylatingTemozolomideAcoustic simulationBlood-brain barrierBrain tumorFocused ultrasoundMRI

Identifiers

PMID38897294
PMCPMC11299340

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.